Mintz Advises on Eledon Pharmaceuticals’ $50 Million Follow-On Offering
November 21, 2025 – Mintz, a leading national law firm, recently advised the underwriters in connection with a $50 million follow-on public offering for Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN). this transaction underscores Mintz’s continued strength in representing companies and investment banks within the biotechnology sector.
The offering involved the sale of common stock, bolstering Eledon Pharmaceuticals’ financial position as it advances its clinical programs. Leerink partners, cantor, and LifeSci Capital served as the joint book-running managers for the offering, leveraging their expertise in the healthcare investment landscape.
Mintz’s portrayal of the underwriters involved a extensive legal review and advisory role throughout the offering process. The Mintz capital markets team was led by William C.Hicks and John Rudy, and included Alok Choksi, Sam Silver, Hannah Karraker, Chris Kinney, and Nicole gaston. Specialized counsel included Ben Zegarelli,providing regulatory guidance; Jenny Chen,offering intellectual property expertise; and Ari Feder,addressing tax considerations. Team members were strategically located across mintz’s Boston, New York, and San Diego offices, demonstrating the firm’s national reach and collaborative approach.
“We are pleased to have supported the underwriters in this important transaction for Eledon Pharmaceuticals,” said William C.Hicks, a member in Mintz’s Corporate Member. “This offering highlights our deep understanding of the complexities involved in capital markets transactions within the biopharmaceutical industry.”
Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on the development and commercialization of novel immunotherapies for autoimmune and inflammatory diseases. The company’s lead candidate, AT-1501, is currently being evaluated in Phase 2 clinical trials for atopic dermatitis and other autoimmune conditions. https://www.eledonpharma.com/
this transaction further solidifies Mintz’s position as a trusted legal advisor to both established pharmaceutical companies and emerging biotechnology firms navigating the intricacies of public offerings and capital markets.
Keywords:
* Primary Keyword: Eledon Pharmaceuticals Follow-On Offering
* Primary Topic: Legal Advisory – Biotechnology Capital Markets
* Secondary Keywords: Mintz Law Firm, Biotechnology Financing, Public Offering, Capital Markets, Leerink Partners, Cantor, LifeSci Capital, AT-1501, Pharmaceutical Law, healthcare Investment.
Sources:
* https://www.mintz.com/ (Mintz Law firm Website)
* https://www.eledonpharma.com/ (Eledon Pharmaceuticals Website)
* https://www.businesswire.com/news/home/20241107005544/en/Eledon-Pharmaceuticals-Announces-50-million-Follow-On-Offering (Business Wire – Eledon Pharmaceuticals Announces $50 Million Follow-On Offering)
* https://www.sec.gov/Archives/edgar/data/1848991/000156459024046619/eldn-424b3.htm (SEC Filing – Eledon Pharmaceuticals Follow-On Offering Prospectus)
Worth a look